Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 812 results for "bristol myers squibb"

Bristol-Myers Squibb Pays up to $1.25B for Promedior
Pharmaceutical Manufacturing Magazine

Bristol-Myers Squibb Pays up to $1.25B for Promedior

Bristol-Myers Squibb Company and Promedior Inc. have entered into an agreement that grants Bristol-Myers Squibb exclusive rights to acquire Promedior and gain worldwide rights to its lead asset PRM-151, a recombinant form of human pentraxin-2 ... Pharmaceutical Manufacturing Magazine, 10 hours ago
Bristol-Myers Squibb to Acquire Promedior Citybizlist, 1 day ago
Seeking Alpha

The Generation Portfolio: Wells Fargo, Disney, MFA Financial, Bristol-Myers Squibb

Sep. 1, 2015 9:04 AM ET | Includes: BMY, DIS, MFA, WFC by: Summary Last week provided some good buying opportunities, but they became fewer as the week went along. I used the market volatility to add Disney, Wells Fargo, Bristol-Myers ...
 Seeking Alpha19 hours ago

Bristol-Myers Squibb makes big pharma deals

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire Promedior, a clinical stage immunotherapy company, and gain worldwide rights to its respiratory drug. The pharma giant ...
 Pharmafile21 hours ago Bristol-Myers Squibb Makes a Move: Up 2.1%  Individual.com1 month ago
Irish Times

Bristol-Myers buys rights to fibrosis drug for up to $1.25bn

Drugmaker Bristol-Myers Squibb said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior for up to $1.25 billion. Bristol-Myers said the deal, which includes a $150 million upfront payment, also gives it ...
 Irish Times1 day ago Bristol-Myers obtains rights to acquire drug developer Promedior for up to $1.25bn  Proactive Investors USA1 day ago Bristol-Myers buys rights to acquire fibrosis drug developer: Reuters  ACQ Magazine1 day ago
Boston Globe

Lexington's Promedior gets $150 million in deal with drug giant

A Lexington life sciences company has signed a $150 million agreement with Bristol-Myers Squibb that could result in an aquisition by the pharmaceutical giant. Promedior, Inc., a company developing drugs to treat diseases such as pulmonary ...
 Boston Globe1 day ago

Telesta Gets FDA Date, Stellar To Be Uplisted To NASDAQ, BMY Inks Deal

Bristol-Myers Squibb Co. (BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. BMY closed ...
 RTTNews.com2 days ago Bristol-Myers Squibb And QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration To Discover Novel Immuno-Oncology Antibodies  TheStreet.com2 days ago Bristol-Myers, QIMR to discover new immuno-oncology antibodies  Pharmaceutical Business Review2 days ago
Bidness Etc

Why Gilead Sciences, Inc. Can Easily Take Over Bristol-Myers Squibb Co

Gilead Sciences, Inc. ( NASDAQ:GILD ) has accumulated a lot of cash during its exceptional stint as leader of the hepatitis C drug market. The company is now being pressurized by investors and analysts to put its cash pile to strategic use, ...
 Bidness Etc5 days ago

Look for Shares of Bristol-Myers Squibb to Potentially Pullback after Yesterday's 1.83% Rise

(Comtex SmarTrend(R)) Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $64.64 to a high of $66.78. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $65.12 on volume of ...
 Individual.com1 month ago SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 2.55% Loss  Individual.com1 month ago
Channel NewsAsia

Bristol-Myers beats forecasts, raises full-year profit view

Bristol-Myers Squibb Co reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines. The U.S. drugmaker, which raised its ...
 Reuters1 month ago Bristol-Myers Squibb beats by $0.17, beats on revenue  Seeking Alpha1 month ago REUTERS - UPDATE 1-Bristol-Myers beats forecasts, raises full-year profit view  Namibia Press Agency1 month ago UPDATE 1-Bristol-Myers beats forecasts, raises full-year profit view  CNBC1 month ago
Motley Fool

Better Dividend Stock: Bristol-Myers Squibb or Merck?

Source: Wikimedia Commons. Dividend stocks are a must-own for any serious investor. After all, they can greatly amplify gains over the long term when used to purchase additional shares through dividend reinvestment programs, or simply generate ...
 Motley Fool3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less